Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-874 intravenous infusions in moderately to severely active Crohn's disease (Phase 2B)
2008-004919-36Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ABT-874 intravenous dose-ranging with Placebo intravenous (2 arms). Primary endpoint: Clinical remission at Week 6. Started Nov 2008; status: terminated.
02
Drugs
briakinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-004919-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004919-36.